NEW YORK ( Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are hitting new 52-week highs and 52-week lows.

It often follows that a stock setting a new 52-week high will continue to set higher and higher highs (and the opposite for a stock setting a new 52-week low), and momentum traders often look to the 52-week-high lists for new stock ideas. Keep in mind, though, that new high prices can also indicate reasons for concern or caution in a stock.

>>6 Crash Stocks to Buy Now

Let's take a closer look at several stocks that hit new 52-week highs today.

Altria ( MO), through its subsidiaries, manufactures and sells cigarettes, other tobacco products, machine-made large cigars and pipe tobacco. It also maintains a portfolio of leveraged and direct finance leases. The stock was recently trading up 5 cents at $27.85 after hitting a 52-week high of $28.14 earlier in the day.

Today's Range: $27.79-$28.14

52-Week Range: $23.20-$28.14

Volume: 8.8 million

Ratings: Of nine analysts covering Altria, four rate it a buy, and five rate it a hold. TheStreet Ratings has a B buy rating on Altria, making it one of the top-rated tobacco stocks.

Activision Blizzard ( ATVI) is an online, personal computer, console and handheld game publisher. It was recently trading off 12 cents, or 0.9%, at $12.82 after hitting a 52-week high of $13.11 earlier in the day.

Today's Range: $12.71-$13.11

52-Week Range: $10.40-$13.11

Volume: 8.6 million

Ratings: Of 19 analysts covering the stock, 16 rate it a buy, and three rate it a hold. TheStreet Ratings' has a B buy rating on Activision.

Activision is one of the top holdings at Whitney Tilson's T2 Partners.

Bristol-Myers Squibb ( BMY) is a global biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. It was recently trading off 2 cents at $32.94 after hitting a 52-week high of $33.20 earlier in the day.

Today's Range: $32.77-$33.20

52-Week Range: $24.97-$33.20

Volume: 7.9 million

Ratings: Of 24 analysts covering the stock, 14 rate it a buy, 10 rate it a hold, and one rates it a sell. TheStreet Ratings' has an A+ buy rating on Bristol-Myers.

One of the top-yielding drug stocks, Bristol-Myers shows up on a recent list of Cramer's Top 3 Dividend Stocks.

IBM ( IBM) provides information technology products and services worldwide. It was recently trading up $2.82, or 1.6%, at $187.92 after hitting a 52-week high of $188 earlier in the day.

Today's Range: $185.65-$188

52-Week Range: $136.70-$188

Volume: 3.1 million

Ratings: Of 20 analysts covering the stock, 12 rate it a buy, and eight rate it a hold. TheStreet Ratings' has an A+ buy rating on IBM, earning it as pot on the top-rated IT services stocks list.

IBM shows up in the portfolios of Bill Miller's Legg Mason Capital Management and Navellier& Associates.

Cephalon ( CEPH) is an international biopharmaceutical company engaged in the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and inflammatory disease. It was recently trading up 2 cents at $81.44 after hitting a 52-week high of $81.45 earlier in the day.

Today's Range: $81.43-$81.45

52-Week Range: $54.15-$81.45

Volume: 2 million

Ratings: Of 20 analysts covering the stock, 17 rate it a hold, and three rate it a sell. TheStreet Ratings' has an A- buy rating on Cephalon, making it one of the top-rated biotech stocks.

Dollar General ( DG) is a discount retailer in the United States and operates convenient-sized stores to deliver everyday low prices on products that families use every day. It was recently trading down 14 cents, or 0.4%, at $38.93 after hitting a 52-week high of $39.69 earlier in the day.

Today's Range: $38.76-$39.69

52-Week Range: $26.65-$39.69

Volume: 1.2. million

Ratings: Of 17 analysts covering the stock, 11 rate it a buy, and six rate it a hold. TheStreet Ratings' has a C hold rating on Dollar General.

Dollar General is a holding in Warren Buffett's portfolio, as well as those of Steve Mandel's Lone Pine Capital and Lee Ainslie's Maverick Capital.

Kimberly-Clark ( KMB) engages in the manufacture and marketing of health care and personal care products worldwide. It was recently trading up 68 cents, or 1%, at $72.13 after hitting a 52-week high of $72.16 earlier in the day.

Today's Range: $71.30-$72.16

52-Week Range: $61-$72.16

Volume: 1.5 million

Ratings: Of 16 analysts covering the stock, six rate it a buy, and 10 rate it a hold. TheStreet Ratings' has an A buy rating on Kimberly-Clark, making it one of the top-rated household products stocks.

Kimberly-Clark, one of the top-yielding consumer non-durables stocks, was included on a list last month of the Top-Yielding, Top-Rated Stocks to Buy.

Deckers ( DECK) is a designer, producer, marketer and brand manager of footwear and accessories. It was recently trading up $1.29, or 1.2% after hitting a 52-week high of $109.90 earlier in the day.

Today's Range: $104.30-$109.90

52-Week Range: $49.60-$109.90

Volume: 1.3 million

Ratings: Of 12 analysts covering the stock, 11 rate it a buy, and one rates it a hold. TheStreet Ratings' has a B buy rating on Deckers.

Deckers shows up on a recent list of 8 Footwear Stocks With Upside but was also featured recently in " 5 Stocks With Big Downside Potential."

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.
Stockpickr is a wholly owned subsidiary of TheStreet.com.

If you liked this article you might like

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

CDC Director Steps Down Following Report She Invested in Big Tobacco Stocks

CDC Director Steps Down Following Report She Invested in Big Tobacco Stocks

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Are Politics and Proxy Firms Killing Your Investment Returns?

Are Politics and Proxy Firms Killing Your Investment Returns?

Hot Biotech ETF Finally Flashes Buy Signal

Hot Biotech ETF Finally Flashes Buy Signal